#1 Clinical Trials Search in Europe

R2R01

R2R01 is an innovative drug currently being studied in clinical trials for its potential benefits in treating worsening heart failure (WHF) and hepatorenal syndrome with acute kidney injury (HRS-AKI). These trials aim to evaluate the safety, tolerability, and effectiveness of R2R01 when combined with standard treatments. The studies involve different dosages and administration methods to determine the optimal use of this new medication in patients with these serious conditions.

Table of Contents

What is R2R01?

R2R01 is a new drug currently being studied for its potential to treat certain serious medical conditions. It is classified as a relaxin agonist, which means it mimics the effects of a natural hormone called relaxin in the body[1]. Relaxin is known to play important roles in various bodily functions, including cardiovascular and kidney health.

What Conditions Does R2R01 Treat?

Based on the ongoing clinical trials, R2R01 is being investigated for two main conditions:

  1. Worsening Heart Failure (WHF): This is a condition where the heart’s ability to pump blood effectively becomes worse, leading to symptoms like shortness of breath, fatigue, and fluid buildup in the body[1].
  2. Hepatorenal Syndrome with Acute Kidney Injury (HRS-AKI): This is a serious condition that occurs in people with advanced liver disease, where kidney function rapidly declines[2].

How Does R2R01 Work?

While the exact mechanism of R2R01 is not fully described in the clinical trial information, we can infer some details based on its classification as a relaxin agonist:

  • In heart failure, R2R01 may help improve blood flow and reduce congestion (fluid buildup) in the body[1].
  • In hepatorenal syndrome, R2R01 might help improve kidney function by affecting blood flow to the kidneys[2].

Current Clinical Trials

R2R01 is currently being studied in two main clinical trials:

  1. Heart Failure Study: This is a Phase 2 trial testing R2R01 in patients with worsening heart failure. The study is comparing different doses of R2R01 to a placebo (a substance with no active drug) when added to standard care treatments[1].
  2. Hepatorenal Syndrome Study: This is also a Phase 2 trial, testing R2R01 in combination with another drug called terlipressin in patients with hepatorenal syndrome and acute kidney injury[2].

These trials aim to determine if R2R01 is safe, well-tolerated, and effective in treating these conditions.

How is R2R01 Administered?

Based on the clinical trial information, R2R01 is administered in the following ways:

  • For heart failure patients, it’s given as a subcutaneous injection (an injection just under the skin) once daily for 7 days[1].
  • For hepatorenal syndrome patients, it’s given in combination with terlipressin. The exact method of administration isn’t specified, but it’s likely also an injection[2].

Safety and Potential Side Effects

As R2R01 is still in clinical trials, its full safety profile is not yet known. The trials are designed to closely monitor for any side effects or safety concerns. Some areas being watched include:

  • Changes in vital signs like blood pressure, heart rate, and oxygen levels[2].
  • Effects on heart rhythm, as measured by ECG (electrocardiogram)[2].
  • Any other adverse events that may occur during treatment[1][2].

Future Prospects for R2R01

If the current Phase 2 trials show promising results, R2R01 may move on to larger Phase 3 trials. These would further test its effectiveness and safety in larger groups of patients. If successful, R2R01 could potentially become a new treatment option for patients with worsening heart failure or hepatorenal syndrome in the future.

It’s important to note that as R2R01 is still in the testing phase, it is not yet available as a prescribed medication. Patients interested in this treatment should speak with their healthcare providers about the possibility of participating in clinical trials.

Aspect Heart Failure Trial Hepatorenal Syndrome Trial
Drug Name R2R01 R2R01 + Terlipressin
Condition Studied Worsening Heart Failure (WHF) Hepatorenal Syndrome – Acute Kidney Injury (HRS-AKI)
Study Phase Phase 2 Phase 2
Study Design Double-blind, placebo-controlled Single-blind, placebo-controlled
Treatment Duration 7 days Up to 14 days
Follow-up Period 23 days after last dose Approximately 76 days
Primary Outcomes Safety, tolerability, dose selection Safety, tolerability, incidence of responders
Secondary Outcomes Effects on NT-pro-BNP, kidney function, diuretic use, hospitalizations, mortality Mortality rates, liver transplant rates
Administration Method Subcutaneous injection Not specified (with terlipressin)

FAQ

  • What is R2R01? R2R01 is a new drug being tested in clinical trials. It is a relaxin agonist, which means it mimics the effects of relaxin, a natural hormone in the body. R2R01 is being studied for its potential benefits in treating worsening heart failure and hepatorenal syndrome.
  • How is R2R01 administered in the clinical trials? In the heart failure trial, R2R01 is given as a daily subcutaneous (under the skin) injection for 7 days. In the hepatorenal syndrome trial, it is administered in combination with another drug called terlipressin, with the exact method of administration not specified in the provided information.
  • What conditions are being studied with R2R01? R2R01 is being studied in clinical trials for two main conditions: worsening heart failure (WHF) and hepatorenal syndrome with acute kidney injury (HRS-AKI). These are serious medical conditions affecting the heart and kidneys.
  • What are the main goals of these clinical trials? The main goals of these trials are to assess the safety, tolerability, and effectiveness of R2R01. Researchers are looking at different doses of the drug and how it works when combined with standard treatments. They are also studying how it affects various markers of heart and kidney function.
  • How long do these clinical trials last? The duration varies between the trials. The heart failure trial lasts up to 51 days total, including a 7-day treatment period. The hepatorenal syndrome trial has a treatment duration of up to 14 days with a follow-up period of approximately 76 days, for a total participation of up to 15 weeks.

Ongoing Clinical Trials on R2R01

  • A study to evaluate the effectiveness of R2R01 in preventing acute kidney injury in patients at high risk following heart surgery.

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Italy

  • Study on the Safety and Effectiveness of R2R01 and Terlipressin for Patients with Hepatorenal Syndrome and Acute Kidney Injury

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Italy

Glossary

  • Worsening Heart Failure (WHF): A condition where the heart's ability to pump blood effectively becomes worse, leading to symptoms like shortness of breath and fluid buildup in the body.
  • Hepatorenal Syndrome (HRS): A serious condition where there is a rapid loss of kidney function in people with severe liver problems.
  • Acute Kidney Injury (AKI): A sudden episode of kidney failure or kidney damage that happens within a few hours or days.
  • Relaxin Agonist: A substance that mimics the effects of relaxin, a natural hormone in the body that can affect blood flow and other bodily functions.
  • Subcutaneous (SC) Injection: A method of giving medication by injecting it under the skin.
  • Standard of Care (SOC): The typical treatment or care given to patients with a specific condition, based on current medical knowledge and practices.
  • NT-pro-BNP: A substance in the blood that can be measured to help diagnose heart failure and assess its severity.
  • Cystatin C: A protein used to measure kidney function, often alongside creatinine.
  • Creatinine Clearance: A test that helps determine how well your kidneys are working by measuring the amount of creatinine removed from the blood by the kidneys.
  • Terlipressin: A medication used to treat certain complications of liver disease, including hepatorenal syndrome.
  • Placebo: A substance with no active medical effects, used in clinical trials to compare against the effects of the drug being tested.
  • Double-Blind Study: A type of clinical trial where neither the participants nor the researchers know who is receiving the actual treatment and who is receiving a placebo.
  • Single-Blind Study: A type of clinical trial where the participants do not know whether they are receiving the actual treatment or a placebo, but the researchers do know.

References